Estrogen receptor-binding fragment-associated antigen 9 (EBAG9) is a primary estrogen-responsive gene that we previously identified in MCF-7 breast cancer cells using the CpG genomic binding-site cloning technique. The expression of EBAG9 protein is often upregulated in malignant tumors, suggesting that this protein is involved in cancer pathophysiology. In the present study, we investigated the role of EBAG9 in host defense against implanted tumors in Ebag9-knockout (Ebag9KO) mice. MB-49 mouse bladder cancer cells were subcutaneously implanted into Ebag9KO and control mice. We found that tumor formation and metastasis to the lung by MB-49 cells were substantially reduced in Ebag9KO mice compared with control mice. The infiltration of CD8 + , CD3
Estrogen receptor-binding fragment-associated antigen 9 (EBAG9) is a primary estrogen-responsive gene that we previously identified in MCF-7 breast cancer cells using the CpG genomic binding-site cloning technique. The expression of EBAG9 protein is often upregulated in malignant tumors, suggesting that this protein is involved in cancer pathophysiology. In the present study, we investigated the role of EBAG9 in host defense against implanted tumors in Ebag9-knockout (Ebag9KO) mice. MB-49 mouse bladder cancer cells were subcutaneously implanted into Ebag9KO and control mice. We found that tumor formation and metastasis to the lung by MB-49 cells were substantially reduced in Ebag9KO mice compared with control mice. The infiltration of CD8 + , CD3
+ and CD4 + T cells into the generated tumors was enhanced in Ebag9KO mice compared with controls. Notably, CD8 + T cells isolated from tumors in Ebag9KO mice exhibited substantial upregulation of immunity-and chemoattraction-related genes, including interleukin-10 receptor, interferon gamma, granzyme A, granzyme B and chemokine (C-X-C motif) receptor 3 compared with CD8 + T cells from tumors in control mice. The CD8 + T cells isolated from tumors in Ebag9KO mice also exhibited enhanced degranulation and increased cytolytic activity. Furthermore, the adoptive transfer of CD8 + T cells isolated from tumors in Ebag9KO host could repress tumor growth by MB-49 cells implanted in wild-type host. These results suggest that EBAG9 modulates tumor growth and metastasis by negatively regulating the adaptive immune response in host defense. EBAG9 could be a potential target for tumor immunotherapy.
INTRODUCTION
Estrogen receptor-binding fragment-associated antigen 9 (EBAG9) is an estrogen-responsive gene that was originally isolated from a CpG island library of MCF-7 human breast cancer cells using a genomic binding-site cloning method.
1 EBAG9 is expressed in estrogen target organs as well as several other organs including the brain, liver, heart and kidney.
2 EBAG9 expression can be induced by estrogen, as observed in cell lines and in ovariectomized mice treated with 17β-estradiol. Although the physiological function of EBAG9 has not been well defined, the molecule may be implicated in cancer pathophysiology based on protein expression studies in breast, 3 ovarian, 4 prostate, 5 hepatocellular, 6 renal cell 7 and bladder cancers. 8 Furthermore, it has been shown that the immunoreactivity of EBAG9 positively correlates to advanced tumor grades and poor prognosis. [3] [4] [5] [6] [7] [8] [9] Therefore, EBAG9 is assumed to promote the progression of malignant tumors.
It has been reported that EBAG9 is localized in the Golgi apparatus and increases O-linked glycan expression. 10 The O-linked glycans, sialyl-Tn, is a carbohydrate antigen overexpressed in several epithelial cancers. 11 It has been shown that sialyl-Tn expression and concomitant changes in the overall O-glycan profile lead to a decreased adhesion and increased migration of MDA-MB-231 breast cancer cells. sialyl-Tn-positive MDA-MB-231 clones exhibit increased tumor growth in severe combined immunodeficiency mice. 11 We have previously shown that EBAG9 has no significant effect on proliferation of Renca cells in vitro, whereas EBAG9 overexpression in Renca cells promotes tumor formation in vivo when the cells are implanted in BALB/c mice. Interestingly, in immunodeficient BALB/c nude mice, tumors generated by EBAG9-overexpressing Renca cells and vector-expressing Renca cells had similar volumes. Thus, EBAG9 is assumed to be a tumorpromoting factor rather than an essential oncoprotein by itself. The difference between EBAG9-overexpressing and vectorexpressing Renca cells in terms of tumor growth in BALB/c mice could be owing to reduced numbers of infiltrating CD8 + T cells in EBAG9-overexpressing Renca cell tumors, as a result of suppression of antitumor immunity in the micrenvironments. 7 Cytotoxic T lymphocytes exclude tumor cells by releasing secretory lysosomes, which contain granzymes and perforin. These lysosomes are produced in the endoplasmic reticulum and subsequently transported to the Golgi complex. 12 It has been shown that the absence of EBAG9 enhances the cytotoxic activity of CD8 + T cells in EBAG9-knockout mice. Although the absence of EBAG9 did not affectlymphocyte development, it led to an increased secretion of granzyme A from cytotoxic T lymphocytes 1 treated with CD3 antibody. EBAG9 is considered to inhibit endosomal-lysosomal trafficking of cytotoxic effectors. 13 To assess the functional relevance of EBAG9 in host defense against tumors, we generated Ebag9-knockout (Ebag9KO) mice by crossing Ebag9 f/f mice with Ayu1-Cre mice, which ubiquitously express Cre recombinase. 14 We show that Ebag9KO mice exhibit strong antitumor immune responses including tumor suppression of lung metastasis. Notably, in Ebag9KO mice, CD8 + T-cell infiltration is significantly increased in generated tumors. We show that CD8 + T cells in Ebag9KO mice exhibit increased expression of interleukin-10 receptor (Il10r), interferon gamma (Ifng), granzyme A (Gzma), granzyme B (Gzmb) and chemokine (C-X-C motif) receptor 3 (Cxcr3), as well as increased degranulation and cytotoxic activity. Moreover, adoptively transferred CD8 + T cells isolated from tumors generated in Ebag9KO mice suppress tumor growth in wild-type mice.
RESULTS

Generation of Ebag9KO mice
To assess the physiological function of EBAG9 in host defense against tumors, we generated Ebag9KO mice by the following steps. We first generated Ebag9 f/f mice by homologous recombination in embryonic stem cells (Figure 1a) . Then, Ebag9 f/f mice were crossed with Ayu1-Cre mice, which ubiquitously expressed Cre recombinase, 14 to remove the neomycin-resistance cassette and exon 2 of the Ebag9 gene. The resulting heterozygous Ebag9 f/+ ; Ayu1-Cre mice were interbred to generate homozygous Ebag9 f/f ; Ayu1-Cre (Ebag9KO) mice. Genotypes of progeny were confirmed by PCR using genomic DNA prepared from tails ( Figure 1b) . To confirm the absence of full-length Ebag9 mRNA and protein expression in Ebag9KO mice, we examined Ebag9 expression in mouse embryonic fibroblasts (MEFs) using quantitative real-time PCR (qRT-PCR) ( Figure 1c ) and western blot analysis (Figure 1d ). Furthermore, we confirmed whether fulllength Ebag9 mRNA was deleted in brain, liver, spleen, bone marrow and thymus in Ebag9KO and control Ebag9 +/+ ;Ayu1-Cre mice using qRT-PCR (Figure 1e ). The expression of full-length Ebag9 mRNA and protein was completely abolished in Ebag9KO MEFs and tissues (including brain, liver, spleen, bone marrow and thymus). Ebag9KO mice seemed to be healthy and fertile without any apparent morphological abnormalities. In addition, mating of Ebag9KO mice produced normal litters.
Loss of Ebag9 in host suppresses tumor growth and lung metastasis by MB-49 bladder cancer cells We investigated the role of EBAG9 in host tumor immunity using Ebag9KO mice with implanted tumors. MB-49 bladder cancer cells, which originated from a carcinogen-induced tumor of bladder epithelial origin in male C57BL/6 mice, 15 were inoculated into Ebag9KO and control mice. MB-49 cells developed smaller tumors in Ebag9KO mice than in control mice 4 weeks after inoculation (Figures 2a and b) . After 4 weeks, the volume of tumors was significantly smaller in Ebag9KO mice than in control mice (2733 ± 1216 versus 5218 ± 1895 mm 3 , n = 8, P o0.01) (Figure 2c ). Furthermore, to determine whether loss of EBAG9 is also involved in tumor metastasis, we investigated lung tissue in Ebag9KO and control mice. Tumor metastasis to the lung was significantly reduced in Ebag9KO mice compared with control mice (Figures 3a and b) . After 4 weeks, the number of metastatic foci in the lung was significantly lower in Ebag9KO mice than in control mice (2.63 ± 2.39 versus 10.50 ± 3.39; Ebag9KO mice, n = 8; control mice, n = 6; P o0.01) (Figure 3c ). These results indicate that EBAG9 is involved in tumor growth and metastasis in vivo. + T cells in implanted tumors of Ebag9KO mice To explore whether EBAG9 modulates the subtype-specific reactivity of T cells against tumors, we examined the number of tumor-infiltrating T cells in the tumors generated in Ebag9KO and control mice by immunohistochemistry using antibodies specific for CD8, CD3, and CD4. Significant increases in the number of CD8 + T cells (56.17 ± 22.05 versus 10.33 ± 11.07; Ebag9KO mice, n = 8; control mice, n = 6; P o 0.01) (Figure 4a ), CD3 + T cells (225.40 ± 39.06 versus 177.92 ± 31.87; Ebag9KO mice, n = 8; control mice, n = 6; Po 0.01) (Figure 4b ), and CD4 + T cells (62.32 ± 27.83 versus 42.91 ± 21.06; Ebag9KO mice, n = 8; control mice, n = 6; P o0.05) (Figure 4c ) in implanted tumors were observed in Ebag9KO mice.
Upregulation of expression of immunity-and chemoattractionrelated genes in CD8 + T cells isolated from tumors generated in Ebag9KO mice To investigate the role of EBAG9 in CD8 + T-cell-mediated immune surveillance, we examined the expression of immunity-and chemoattraction-related genes in CD8 + T cells isolated from tumors generated in Ebag9KO and control mice. The expression of Il10r (Figure 5a ), Ifng (Figure 5b ), Gzma (Figure 5c ), Gzmb (Figure 5d ) and Cxcr3 (Figure 5e ) was upregulated in CD8 + T cells isolated from tumors generated in Ebag9KO mice compared with control mice (each n = 3, P o0.05). We also confirmed that there was no detectable expression of full-length Ebag9 mRNA (Figure 5f ) in the CD8 + T cells isolated from tumors generated in Ebag9KO mice by qRT-PCR (n = 3, P o 0.01). To measure the purity of CD8 + T cells isolated from tumors generated in Ebag9KO and control mice, we stained the isolated cells with anti-CD8a-FITC antibody and analyzed the cells by flow cytometry. CD8 + T cells typically constituted 490% of the isolated cells (data not shown). These results indicate that loss of EBAG9 resulted in the upregulation of genes related to cytotoxicity and chemoattraction.
Loss of EBAG9 induces host immune surveillance We next performed a degranulation assay ( Figure 6a ) and a cytotoxicity assay (Figure 6b ) to investigate whether the loss of EBAG9 expression influenced the activity of CD8 + T cells. CD8 + T cells isolated from tumors generated in Ebag9KO mice exhibited increased degranulation and cytotoxicity, suggesting that the loss of EBAG9 contributes to the fusion of lysosomes with the plasma membrane in CD8 + T cells. Furthermore, we investigated whether the CD8 + T cells isolated from tumors generated in Ebag9KO mice are involved in the suppression of bladder cancer MB-49 tumor growth. We intravenously transferred CD8 + T cells isolated from tumors generated in Ebag9KO or control mice into C57BL/6 mice. Then, MB-49 cells were inoculated into the recipient mice. Adaptively transferred CD8 + T cells isolated from tumors generated in Ebag9KO mice suppressed tumor growth of MB-49 cells (Figures 6c and d control mice. Notably, in Ebag9KO mice, the numbers of infiltrating CD8 + , CD3 + and CD4 + T cells were significantly increased in tumors derived from MB-49 cells, and the expression of immunity-and chemoattraction-related genes was upregulated in CD8 + T cells isolated from these tumors. EBAG9 was also found to be involved in the regulation of lysosome-mediated degranulation and cytotoxic activity of CD8 + T cells. Furthermore, the adoptive transfer of CD8 + T cells isolated from tumors in Ebag9KO host could repress tumor growth by MB-49 cells implanted in wildtype host. These results suggest that EBAG9 acts as a negative regulator of CD8 + T cells in host immune surveillance against tumors.
In antitumor immunity, T-cell-mediated immune surveillance is a main host defense mechanism. 16 In this context, IL-10 is assumed to be an immunosuppressive cytokine within the tumor microenvironment. Recent studies have revealed, however, that IL-10 has rather diverse functions, as the molecule also induces potent antitumor responses. [17] [18] [19] It has been shown that IL-10 induces the proliferation and cytotoxic activity of CD8 + T cells and functions as a chemoattractant for CD8 + T cells. [20] [21] [22] [23] Here we have shown that the loss of EBAG9 enhances antitumor responses in CD8 + T cells, as these cells exhibited higher expression of Il10r in Ebag9KO mice than in controls. IL-10 activates CD8 + T cells in vitro, and treatment with IL-10 leads to tumor rejection in multiple tumor-bearing mouse models. 24, 25 IL-10 also increases the expression of IL-10R in activated CD8 + T cells. 26 Furthermore, IL-10 treatment induces expression of interferon γ (IFN-γ) by CD8 + T cells, which in turn increases levels of chemokines, such as CXCL9 (monokine induced by interferon, or MIG) and CXCL10 (interferon-induced protein of 10 kDa, or IP-10), in the tumor and serum. 27 These chemokines act as chemoattractants for T cells, suggesting a positive feedback loop of IFN-γ-producing CD8 + T-cell recruitment into the tumor, initiated by IL-10. Indeed, such a feedback loop was proposed for mice bearing mammary tumors and treated with IL-10. 28 Overall, these results suggest that EBAG9 in CD8 + T cells may act as a negative regulator of antitumor responses and that loss of EBAG9 function results in the activation of IL-10/IL-10R signaling.
CXCR3 is an inflammatory chemokine receptor present on activated T cells, particularly CD4 + T cells and CD8 + T cells. 29, 30 CXCR3 has an important role in T-cell trafficking and function. Chemokines such as CXCL9, CXCL10 and CXCL11 function as CXCR3 ligands that induce cell migration. [29] [30] [31] [32] It has been reported that these chemokines are abundantly expressed in CXCR3-positive cells involved in human and mouse cancers. [33] [34] [35] [36] [37] We have shown here that the expression of Ifng and Cxcr3 is upregulated in Ebag9-deficient CD8 + T cells. Our findings suggest that EBAG9 could be a negative regulator of cytotoxic activity and chemoattraction of T cells, resulting in the suppression of tumor immunosurveillance.
Degranulation of mature antigen-specific CD8 + T cells is a requisite process for perforin-and granzyme-mediated killing of target cells. 38 We found that the loss of EBAG9 increased the expression of a degranulation marker, CD107, in CD8 + T cells that had infiltrated tumors. This suggests that EBAG9 is involved in the regulation of endosomal trafficking of lytic granules in tumorinfiltrating T cells. Our findings are consistent with a previous report that EBAG9 deficiency increased the release of lytic granule contents and enhanced cytolytic capacity. 13 We assume that the enhanced degranulation activity of CD8 + T cells will primarily contribute to the magnitude of tumor inhibitory effects of Ebag9KO host in this study. We also consider that CD8 + T cells with increased degranulation activity will secrete more amounts of cytokines and chemokines, such as IL-10, which lead to further chemoattraction of CD8 + T cells and other immunerelated cells into the tumors. [20] [21] [22] [23] The number of infiltrating effector cells can be another major important factor for the magnitude of antitumor immunity, if the secretion of lytic 
granules from CD8
+ T cells is stable and the cell frequency is a unique factor for the total amount of cytolytic activity.
In summary, our results show that EBAG9 is a critical factor that regulates T-cell-mediated antitumor immunity in vivo. Given these results and our previous findings regarding EBAG9 overexpression in cancers, we conclude that EBAG9 contributes to the promotion of tumor proliferation and the reduction of tumor immune surveillance. The management of EBAG9 expression in both tumors and their microenvironment could be an alternative therapeutic option for advanced stages of cancers.
MATERIALS AND METHODS Reagents
Human anti-EBAG9 monoclonal antibody was generated against a glutathione S-transferase-EBAG9 fusion protein. 9 Antibodies against CD3 (Dako, Tokyo, Japan), CD4 (H-370; Santa Cruz Biotechnology, Dallas, DX, USA), CD8a (H-160; Santa Cruz Biotechnology), CD107-PE (1D4B; BD Pharmingen, Tokyo, Japan), CD8a-FITC (53-6.7; BD Pharmingen) and anti-β-actin (AC-74; Sigma-Aldrich, Tokyo, Japan) were purchased.
Bladdercancer cells MB-49 mouse bladder cancer cells, which originated from a carcinogeninduced tumor of bladder epithelial origin in male C57BL/6 mice, 15 were maintained in RPMI 1640 containing 10% fetal calf serum, penicillin (50 U/ml) and streptomycin (50 mg/ml).
Generation of Ebag9KO mice
To generate Ebag9 floxed (Ebag9 f/f ) mice, genomic DNA covering the Ebag9 locus was obtained from a 129SV/J mouse genomic library (Agilent Technologies, Santa Clara, CA, USA) by screening with a mouse Ebag9 cDNA probe. The resulting DNA fragments were assembled into a targeting vector in which the Venus gene was inserted in frame at the translation initiation codon of the Ebag9 gene and exon 2 was floxed by loxP sites (Figure 1a) . After linearization, the targeting vector was electroporated into E14 embryonic stem cells. 39, 40 G418-resistant colonies were selected and analyzed for homologous recombination by PCR and Southern blot hybridization. The primers for the PCR screening were 5′-GAGCACAAGGACAGATTGACCACGTCATGCAGGA-3′ and 5′-GTTGTGCCC AGTCATAGCCGAATAGCCTCTCCAC-3′. Positive clones were verified by Southern blot hybridization in which genomic DNA digested with PvuII was probed with a 414-bp DNA fragment corresponding to the 5ʹ upstream region of the Ebag9 gene. The correctly targeted embryonic stem cells were injected into C57BL/6 blastocysts and transferred into pseudopregnant females. Chimeric offspring were bred to C57BL/6 mice expressing the Cre recombinase gene under the control of the ubiquitous Ayu1 promoter (Ayu1-Cre).
14 Genotypes were determined by PCR analysis of tail DNA (Figure 1b) . For amplification of the wild-type allele, the sense and antisense primers A (5′-GGGAAATTACTGTTGCTGGC-3′) and B (5′-CAGCTGAAGTATGTGTGCC-3′) were used (Figure 1a) . For genotyping of Ayu1-Cre mice, primers derived from Cre (5′-CCTGGAAAATGCTTCTG TCCGTTTGCC-3′ and 5′-GAGTTGATAGCTGGCTGGTGGCAGATG-3′) were used to amplify a 653-bp product. Mice were kept under specific pathogen-free conditions and fed dry food and water ad libitum. All experiments were performed according to the guidelines for the care and use of laboratory animals of both the University of Tsukuba and Saitama Medical University.
Quantitative real-time PCR Total RNAs were extracted from MEFs, brain, liver, spleen, bone marrow, thymus and CD8 + T cells of Ebag9KO and control mice using ISOGEN reagent (Nippon Gene, Tokyo, Japan), and first-stand cDNA was generated with 1 μg of total RNA using SuperScript III reverse transcriptase (Invitrogen, San Diego, CA, USA) and oligo(dT) 20 primer. To evaluate the expression of mouse Ebag9, Cd8, Il10r, Ifng, Gzma, Gzmb and Cxcr3 mRNA, RT-PCR was done using primers specific for mouse Ebag9 (sense, 5′-GCAACAGTGTTCTCGTTCCT-3′; antisense, 5ʹ-TGGGCAAAGTTATTTGATC TCC-3′), Cd8 (sense, 5′-GCTACCACAGGAGCCGAAAG-3′; antisense, 5ʹ-TGG GCTTGCCTTCCTGTCT-3′), Il10r (sense, 5′-GAGCCCGTCTGTGAGCAAAC-3′; antisense, 5′-GATGGCCACGACGATCCA-3′), Ifng (sense, 5′-CCTTCTTCAGCAA CAGCAAGGCGAA-3′; antisense, 5′-GCAACAGCTGGTGGACCACTCG-3′), Gzma (sense, 5′-TGACTGCTGCCCACTGTAACG-3′; antisense, 5′-CGGCATCT GGTTCCTGGTTTCACA-3′), Gzmb (sense, 5′-CCATCGTCCCTAGAGCTGAG-3′; antisense, 5′-TTGTGGAGAGGGCAAACTTC-3′) and Cxcr3 (sense, 5′-TCGGAC TTTGCCTTTCTTCTG-3′;
antisense, 5′-CTCTCGTTTTCCCCATAATCGT-3′). Mouse Gapdh was used as an internal control. The results are shown as mean values ± s.d. Statistical analysis was carried out using Student's t-test. 
Immunohistochemistry
Immunohistochemical studies were done using the streptavidin-biotin amplification method with horseradish peroxidase detection. Paraffin sections of tumors were blocked in 0.3% H2O2 (15 min) and incubated overnight with specific antibodies against CD3, CD4 or CD8 for bladder cancer tumors (1:200 dilution). Sections were incubated with antirabbit EnVision+ reagent (Dako) and counterstained with hematoxylin (Wako, Tokyo, Japan). The numbers of tumor-infiltrating lymphocytes positive for CD8, CD3 or CD4 expression were microscopically examined in the highpower field of view at a magnification of 400 × . A spleen specimen from a control mouse was used as a positive control.
CD8 + T-cell isolation
Mouse CD8 + T cells were isolated from tumor tissue using a mouse CD8α-positive selection kit (STEMCELL Technologies, Vancouver, BC, Canada), according to the manufacturer's protocol. Isolated CD8 + T cells were activated and expanded using a T-cell activation/expansion kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
Degranulation assay CD8
+ T cells isolated from tumors generated in Ebag9KO and control mice were washed with PBS and fixed with 70% ethanol. Cells were then washed and resuspended in FACS buffer (10 mM HEPES (pH 7.4), 140 mM NaCl, 2.5 mM CaCl 2 ) in the presence of anti-CD107a or IgG2a conjugated with PE. Degranulation was evaluated by flow cytometry and calculated as the percentage of cells that showed an increase in CD107a membrane fluorescence.
Cytotoxicity assay MB-49 mouse bladder cancer cells were used as target cells. Target cells were incubated with effector CD8 + T cells isolated from tumors generated in Ebag9KO and control mice at various effector/target ratios in a final volume of 100 μl for 8 h at 37°C. Lactate dehydrogenase released from cells with damaged membranes was examined using the CytoTox 96 NonRadioactive Cytotoxicity Assay (Promega, Madison, WI, USA) and absorbance was measured at 490 nm. Experiments were done in triplicate. The results are shown as mean values ± s.d. Statistical analysis was carried out using Student's t-test.
Adaptive CD8 + T-cell transfer
Mouse CD8 + T cells were isolated from tumor tissue in Ebag9KO and control mice using mouse CD8α-positive selection kit (STEMCELL Technologies). The CD8 + T cells were intravenously injected into C57BL/6 mice (2 × 10 6 cells per mouse), after 2 days, the mice were inoculated with MB-49 cells (5 × 10 5 cells per mouse) that were suspended in 50 μl of PBS with 50 μl of Matrigel into the flank. Tumor volume was measured once or twice a week. The results are shown as mean values ± s.d. Statistical analysis was carried out using Student's t-test.
